This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly, Ono develop and market respiratory pharmaceutical
18 Jun 2003
Eli Lilly signed a letter of intent for an exclusive worldwide license--except in Japan, South Korea, and Taiwan--to Ono Pharmaceutical's (prostaglandins and enzyme inhibitors) Phase II sivelestat for acute lung injury and acute respiratory distress syndrome requiring mechanical ventilation.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?